John Theurer Cancer Center Announces Positive Results with New Targeted ... Fort Mills Times The data presented in NEJM today reports on a single arm open label phase II study, with 125 patients with iNHL refractory to the two most common therapies used in iNHL (i.e. monoclonal antibody rituximab and alkylating agent). Patients were given ... |
